Skip to content Skip to footer

BI Collaborates with Re-Vana Therapeutics to Develop Long-Acting Therapeutics for Eye Diseases

Shots: BI & Re-Vana Therapeutics have entered into a strategic collaboration & license agreement to develop extended-release therapies for eye diseases As per the deal, BI will obtain target exclusivity, while Re-Vana will receive over $1B in total potential deal value for the initial 3 targets, incl. upfront, development, regulatory, & commercial milestones, plus royalties…

Read more

GSK Enters a ~$12.5B Deal with Hengrui Pharma to Develop up to 12 Novel Therapeutics Across Various Indications

Shots: GSK will obtain an exclusive global license to HRS-9821, an add-on maintenance therapy for COPD, along with exclusive option rights to develop & commercialize ~11 more programs in oncology, respiratory, immunology, & inflammation globally (excl. mainland China, Hong Kong, Macau, & Taiwan for both) Each of the ~11 additional programs will have its own…

Read more

PharmaShots Weekly Snapshots (Jul 21, 2025 – Jul 25, 2025)  

This week, PharmaShots’ news was all about the updates on clinical trials, Regulatory, Pharma, MedTech, M&A, DigiHealth, Animal Health and Biosimilars. Check out our full report below:  AstraZeneca Reports P-III (FLAURA2) Trial Findings on Tagrisso Regimen to Treat EGFRm NSCLC  Read More: AstraZeneca  Sun Pharma Reports Topline Data from P-III (INSPIRE-1 & INSPIRE-2) Trials of…

Read more

Eli Lilly & Gate Bio

Eli Lilly Signs an ~$856M Deal with Gate Bioscience to Develop Molecular Gate Therapeutics

Shots: Eli Lilly has entered into a collaboration & license agreement with Gate Bioscience to identify, develop, & commercialize molecular gate drugs, leveraging Gate’s molecular gate drug discovery engine As per the deal, Gate will receive ~$856M in total, incl. an upfront payment, equity investment, & development, regulatory, & commercial milestones, along with tiered royalties…

Read more

Matchpoint Therapeutics and Novartis

Matchpoint Therapeutics Collaborates with Novartis to Develop Oral Covalent Inhibitors for Various Inflammatory Diseases

Shots: Matchpoint & Novartis have entered into an exclusive option & license agreement to develop & commercialize oral covalent inhibitors targeting a transcription factor in inflammatory diseases using Matchpoint’s ACE platform As per the deal, Matchpoint will lead all research activities through development candidate selection with funding from Novartis. Matchpoint will receive $60M in upfront & funding…

Read more

Kling Bio Joins Forces with Sanofi to Identify Neutralizing Antibodies

Shots: Kling Bio has entered into a collaboration & license option agreement with Sanofi to discover antibodies & epitopes leveraging Kling Bio’s Kling-Select platform Collaboration aims to discover & characterize monoclonal antibodies with strong neutralizing activity against human viral pathogen to allow development of novel antiviral therapies Kling-Select is a validated B cell immortalization platform…

Read more

PharmaShots Weekly Snapshots (Jul 14, 2025 – Jul 18, 2025)   

This week, PharmaShots’ news was all about the updates on clinical trials, Regulatory, Pharma, MedTech, M&A, DigiHealth and Biosimilars. Check out our full report below: Takeda Reports P-III (FirstLight & RadiantLight) Trials Data on Oveporexton for Narcolepsy Type 1 (NT1) Read More: Takeda AstraZeneca Reports P-III (BaxHTN) Trial Results of Baxdrostat for Uncontrolled or Treatment Resistant…

Read more

NKGen Biotech Partners with HekaBio to Accelerate Troculeucel Development in Japan

Shots: NKGen Biotech has partnered with HekaBio to accelerate the regulatory, manufacturing & commercial development of troculeucel in Japan As per the collaboration, HekaBio will lead trials & handle regulatory activities with Japan’s PMDA for pre-market approval of troculeucel in neurodegenerative diseases, incl. Alzheimer’s & Parkinson’s. Also, HekaBio aims for first pts dosing in Japan…

Read more